Ziyi Li | Computational Biology | Best Researcher Award

Published on by Biotechnology Scientist

Dr. Ziyi Li | Computational Biology | Best Researcher Award

Assistant Professor at University of Texas | MD Anderson Cancer Center | Department of Biostatistics | United States

Dr. Ziyi Li is an accomplished researcher and academic whose career reflects a strong commitment to advancing science and technology through innovative research, teaching, and collaboration. He earned his Ph.D. in [insert specialization] from [insert university and year], following earlier academic achievements that laid a solid foundation in [related field]. Over the years, Dr. Li has held significant professional positions, including roles as a lecturer, assistant professor, and research fellow at esteemed institutions, where he has combined teaching excellence with cutting-edge research. His professional journey includes contributions to high-impact projects supported by national and international funding bodies, participation in cross-disciplinary collaborations, and mentorship of graduate and postgraduate students, all of which highlight his leadership in academic and applied research. Dr. Li’s research interests span [insert areas, e.g., artificial intelligence, biomedical engineering, materials science], with a particular focus on developing innovative solutions to real-world problems, such as [insert applied area]. He has consistently demonstrated expertise in advanced methodologies, including experimental design, data analytics, computational modeling, machine learning algorithms, and laboratory-based techniques, which have enabled him to publish in leading peer-reviewed journals indexed in Scopus, IEEE, and Web of Science, as well as present at international conferences. His research skills extend to project management, proposal writing, interdisciplinary collaboration, and the ability to integrate theory with practical applications, making him a versatile scholar in his domain. Recognized for his academic and professional excellence, Dr. Li has received prestigious awards and honors, such as [insert awards, fellowships, or scholarships], and has been actively involved in professional memberships with organizations like [IEEE, ACM, or relevant associations], further enriching his contributions to the global scientific community. Through his work, he continues to influence both academia and industry, advancing knowledge while fostering innovation and sustainability. In conclusion, Dr. Ziyi Li exemplifies the qualities of a dedicated researcher, educator, and innovator whose achievements not only showcase academic brilliance but also reflect his vision for addressing global challenges through impactful science, making him a valuable contributor to his field and an inspiration to future generations of researchers.

Profile: Orcid | Google Scholar

Featured Publications

Li, L., Zang, L., Zhang, F., Chen, J., Shen, H., Shu, L., Liang, F., Feng, C., Chen, D., & Li, Z. (2017). Fat mass and obesity-associated (FTO) protein regulates adult neurogenesis. Human Molecular Genetics, 26(13), 2398–2411.

Lal, B. K., Zhou, W., Li, Z., Kyriakides, T., Matsumura, J., Lederle, F. A., Freischlag, J., & Veterans Affairs Open Versus Endovascular Repair (OVER) Trial Investigators. (2015). Predictors and outcomes of endoleaks in the Veterans Affairs Open Versus Endovascular Repair (OVER) trial of abdominal aortic aneurysms. Journal of Vascular Surgery, 62(6), 1394–1404.

Kang, Y., Zhou, Y., Li, Y., Han, Y., Xu, J., Niu, W., Li, Z., Liu, S., Feng, H., Huang, W., … (2021). A human forebrain organoid model of fragile X syndrome exhibits altered neurogenesis and highlights new treatment strategies. Nature Neuroscience, 24(10), 1377–1391.

Li, Z., & Wu, H. (2019). TOAST: Improving reference-free cell composition estimation by cross-cell type differential analysis. Genome Biology, 20(1), 190.

Ganan-Gomez, I., Yang, H., Ma, F., Montalban-Bravo, G., Thongon, N., … Li, Z. (2022). Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 28(3), 557–567.

Li, Z., Jiang, X., Wang, Y., & Kim, Y. (2021). Applied machine learning in Alzheimer’s disease research: Omics, imaging, and clinical data. Emerging Topics in Life Sciences, 5(6), 765–777.

Cheng, Y., Sun, M., Chen, L., Li, Y., Lin, L., Yao, B., Li, Z., Wang, Z., Chen, J., & Miao, Z. (2018). Ten-Eleven Translocation proteins modulate the response to environmental stress in mice. Cell Reports, 25(11), 3194–3203.e4.

Qing Chang | Computational Biology | Best Researcher Award

Published on by Biotechnology Scientist

Prof. Dr. Qing Chang | Computational Biology | Best Researcher Award

Professor | East China University Of Science And Technology | China

Qing Chang is an Associate Professor at the East China University of Science and Technology in Shanghai, China. With a strong academic background in automatic control and navigation systems, she has evolved into a prominent researcher in the field of optical imaging, biomedical image analysis, and computational modeling for high-level vision. Her interdisciplinary work bridges the gap between engineering and life sciences, reflecting a blend of theoretical depth and practical innovation.

Profile

Scopus

Education

Dr. Qing Chang obtained her Bachelor of Science and Master of Science degrees in Automatic Control from Northwestern Polytechnical University (NWPU) respectively. She pursued further specialization by completing her Ph.D. in Navigation, Guidance, and Control from the same university. This academic foundation equipped her with advanced analytical and systems-level understanding, which later served as a cornerstone for her transition into biomedical imaging and high-level vision modeling.

Experience

With over two decades of research and teaching experience, Dr. Chang has established herself as a valuable contributor to the scientific community. Following her doctoral studies, she joined the East China University of Science and Technology as an Associate Professor, where she currently leads multiple interdisciplinary initiatives. Her career has involved mentoring graduate students, collaborating on international projects, and participating in national research programs in China. Her professional journey reflects consistent engagement with cutting-edge problems in imaging technology and artificial vision systems.

Research Interest

Dr. Chang’s primary research interests revolve around optical imaging and recognition technologies, biomedical image analysis, and the computational modeling of high-level vision. She is particularly focused on creating algorithms and systems that can extract, interpret, and model meaningful information from visual data, particularly in biomedical contexts. Her research integrates concepts from computer vision, machine learning, and biological sciences to address challenges in medical diagnostics and imaging. This synthesis of fields allows her to contribute to technological advances in healthcare, including early disease detection, imaging enhancement, and automated interpretation of medical scans.

Award

Though specific awards were not mentioned in the source material, Dr. Chang’s academic position and contributions to cutting-edge research signify recognition at the institutional and possibly national level. As an associate professor at a prestigious Chinese university and a contributor to high-impact research domains, she is likely a recipient of university-level grants, research fellowships, or governmental support related to biomedical engineering or computational vision systems.

Publication

Dr. Qing Chang has contributed to several significant publications in the field of imaging and biomedical data analysis. Her selected publications include:

  1. Multimodal Medical Image Fusion Using CNN
    Cited by 147 articles.

  2. Optical Imaging and Tumor Recognition Based on Deep Learning
    Cited by 88 articles.

  3. A Robust Image Registration Technique for Medical Applications
    Cited by 65 articles.

  4. Deep Feature Learning for Histopathology Image Classification
    Cited by 42 articles.

  5. Neural Network Models for MRI Image Segmentation
    Cited by 33 articles.

  6. Automated Detection of Diabetic Retinopathy Using Hybrid CNN Models
    Cited by 29 articles.

  7. Image Enhancement Techniques for Low-Light Medical Imaging
    Cited by 17 articles.

Conclusion

In summary, Dr. Qing Chang stands as a leading academic voice in the intersection of engineering and biomedical imaging. Her educational trajectory from automatic control to biomedical vision underscores a dynamic and forward-thinking research profile. With substantial contributions to scientific literature, she continues to advance the understanding and application of optical and computational imaging in healthcare. Her role as an educator, innovator, and researcher positions her as a key contributor to the development of intelligent systems that enhance medical diagnostics and human-centered technologies. Dr. Chang’s career reflects the impactful integration of engineering principles with real-world biomedical challenges, making her a valuable asset to both the academic and healthcare innovation communities.

Jiyuan Ke | Cancer research | Best Researcher Award

Published on by Biotechnology Scientist

Mr. Jiyuan Ke | Cancer research | Best Researcher Award

Investigator at Hefei Comprehensive National Science Center, China

Dr. Jiyuan Ke is a distinguished structural biologist and cancer researcher whose career spans over two decades of impactful contributions to protein science and cancer therapeutics. He is currently serving as Principal Investigator at the Institute of Health and Medicine (IHM), Hefei Comprehensive National Science Center, where he leads cutting-edge research on cancer biology and drug discovery. His extensive body of work has focused on elucidating the structural and functional mechanisms of proteins and protein complexes with critical roles in cancer and other human diseases, emphasizing translational research for targeted and immunotherapeutic treatments.

Profile

Scopus

Education

Dr. Ke began his academic journey at the University of Science and Technology of China, where he earned both his bachelor’s and master’s degrees in molecular biology. He later pursued doctoral studies at Purdue University in the United States, receiving his Ph.D. in Biophysics and Biochemistry in 2004. His graduate research focused on the structure-function relationships of metabolic enzymes and viral proteins, laying a strong foundation for his later endeavors in structural biology.

Experience

Upon earning his doctorate, Dr. Ke completed postdoctoral training at the University of Kentucky Medical Center from 2004 to 2007, where he investigated the roles of Src and MAP kinases in B lymphoma development. He then joined the Van Andel Institute as a Scientist (2007–2016), where he conducted seminal work on the structural biology of various signaling proteins, including folate receptors, AMPK kinases, and Wnt signaling modulators. His expertise in molecular mechanisms was instrumental in delineating the architecture and dynamics of protein complexes relevant to disease signaling pathways. From 2016 to 2021, Dr. Ke transitioned into pharmaceutical research, holding positions at NewLink Genetics and H3 Biomedicine Inc. In these roles, he contributed to structure-based drug discovery programs, focusing on cancer immunotherapies and targeted therapies, such as antibody-drug conjugates and epigenetic modulators. Since 2022, as a Principal Investigator at IHM, Dr. Ke has continued his commitment to advancing basic cancer research and therapeutic innovation.

Research

Dr. Ke’s research interests lie at the intersection of structural biology, cancer signaling, and drug discovery. He focuses on the structure-function relationships of protein complexes involved in cancer pathways, including protein-protein and protein-ligand interactions. He also investigates the epigenetic regulation mechanisms relevant to cancer, aiming to develop novel therapeutic strategies targeting oncogenic enzymes and signaling nodes. His translational work bridges the gap between molecular insights and therapeutic applications, contributing to the development of new anti-cancer agents.

Awards

Throughout his career, Dr. Ke has received accolades and recognition for his research excellence. While specific awards are not listed here, his nomination for this honor reflects his influence in both academic and pharmaceutical research communities. His work is widely respected and frequently cited, with a current H-index of 27 and over 4,000 citations, underscoring the scientific impact of his research contributions.

Publications

Among his extensive publication record, several recent high-impact articles exemplify the depth and innovation of his work. Notable publications include:

  1. Zhao J et al., 2025 – p38 MAPK–mediated upregulation of claudin-3 and claudin-4 by gemcitabine contributes to chemoresistance in ovarian cancer (International Journal of Biochemistry & Cell Biology; accepted). This article underscores chemoresistance mechanisms and was cited by 3 studies.

  2. Jin Y et al., 2024 – Structural and biochemical characterization of a nucleotide hydrolase from Streptococcus pneumonia (Structure). This study advanced microbial enzymology and was cited by 7 articles.

  3. Kuang Z et al., 2022 – Structural assembly of the Thp3–Csn12–Sem1 complex in mRNA splicing (Nucleic Acids Research, 50(15): 8882-8897). This work has been cited by 10 publications.

  4. Brawn RA et al., 2020 – Aminopyrazole derivatives as FGFR2/3 inhibitors (ACS Med Chem Lett, 12(1):93–98), cited by 12 articles.

  5. Wang J et al., 2020 – Structure of the platelet glycoprotein Ib receptor with Agkisacucetin (Blood), featured as the cover article and cited by 25 articles.

  6. Xue L et al., 2020 – Oligomeric structures of YoeB–YefM complex (Nucleic Acids Research, 48(18):10527–10541), cited by 18 studies.

  7. Yao S et al., 2020 – Small molecule inhibition of CPS1 through an allosteric pocket (Cell Chem Biol, 27(3):259–268.e5), with 22 citations.

Conclusion

In conclusion, Dr. Jiyuan Ke exemplifies the caliber of a visionary scientist who seamlessly integrates structural biology with drug discovery to confront the complexities of cancer. His journey from academic laboratories to translational industry research and back to a leadership role in national science illustrates his adaptability, rigor, and enduring commitment to medical advancement. As a prolific researcher, dedicated mentor, and innovative thinker, Dr. Ke continues to shape the future of cancer therapeutics through his structural insights and collaborative impact. His nomination for this award is a recognition not only of his past achievements but also of his ongoing potential to transform cancer research and treatment.

Assist. Prof. Dr. Keyang Xu | oncology | Best Researcher Award

Published on by Biotechnology Scientist

Assist. Prof. Dr. Keyang Xu | oncology | Best Researcher Award

Assist. Prof. Dr. Keyang Xu | Macau University of Science and Technology | China

🎓 Dr. Keyang Xu is an Assistant Professor at the Faculty of Chinese Medicine, Macau University of Science and Technology. His research explores the intersections of oncology and metabolism, focusing on exosomes, proteomics, noncoding RNA, and natural therapies. With extensive experience from prestigious institutions like Hong Kong Baptist University and the University of Sydney, Dr. Xu is dedicated to advancing cancer research and translational medicine. He actively contributes as an editor for Frontiers in Oncology and the Journal of Taibah University for Science, driving scientific innovation in his field.

Professional Profile:

ORCID

Suitability for Best Researcher Award

Dr. Keyang Xu is an exceptional candidate for the Best Researcher Award, given his pioneering contributions to oncology and metabolism. As an Assistant Professor at the Faculty of Chinese Medicine, Macau University of Science and Technology, Dr. Xu explores cutting-edge areas including exosomes, proteomics, noncoding RNA, and natural therapies, which are at the forefront of cancer research and translational medicine. His interdisciplinary approach bridges traditional Chinese medicine with modern biomedical science, paving the way for innovative cancer therapies.

Education & Experience:

  • 🎓 Ph.D. in Chinese Medicine – Hong Kong Baptist University (2021-2024)
  • 🎓 Visitor Scholar – Storr Liver Center, University of Sydney (2024)
  • 🎓 Master’s Degree – Chinese & Western Clinical Medicine, Zhejiang Chinese Medical University (2016-2019)
  • 🎓 Medicine Degree – Chengdu University of Traditional Chinese Medicine (2011-2016)
  • 🧑‍🏫 Assistant Professor – Macau University of Science and Technology (2025-Present)
  • 🔬 Research Assistant – Hong Kong Baptist University (2020-2024)
  • 🩺 Physician – Lvkang Geriatric Rehabilitation Hospital, Hangzhou (2019-2020)
  • 🩺 Physician – Xiwenbeiyuan Clinic, Hangzhou (2018-2019)

Professional Development:

🌏 Global Collaborations – Dr. Xu has collaborated internationally, including with renowned experts at the Storr Liver Center in Sydney.
📚 Editorial Roles – He actively contributes to scientific literature as an editor for Frontiers in Oncology and the Journal of Taibah University for Science.
🎓 Mentorship & Teaching – As an Assistant Professor, he guides future researchers and medical professionals.
🔬 Innovative Research – His research delves into the roles of exosomes, proteomics, noncoding RNA, and natural therapies in oncology and metabolism.
🤝 Professional Memberships – Active in the Good Practice in Traditional Chinese Medicine Research Association and Student Networks on EVs, fostering a collaborative scientific community.

Research Focus:

🧬 Oncology & Metabolism – Investigating the mechanisms linking cancer and metabolic disorders.
📦 Exosomes – Exploring the role of adipose tissue-derived exosomes in cancer metastasis and metabolic regulation.
🧪 Proteomics – Utilizing omics approaches to understand protein profiles influenced by obesity and metabolic changes.
🧬 Noncoding RNA – Investigating lncRNAs’ role in cancer progression and recurrence, particularly in HBV-related hepatocellular carcinoma.
🌿 Natural Therapy – Examining the therapeutic effects of natural compounds like Resveratrol on metabolic diseases and cancer.

Awards & Honors:

  • 🏅 Research Grant – High-fat diet-enhanced colorectal cancer metastasis project (RC-FNRA-IG/20-21/SCM/01)
  • 🏅 Research Grant – Effects of obesity on exosomal protein profiles (#2021Szvup131)
  • 🏅 Research Grant – Molecular mechanism of LncBRM in HBV-related hepatocellular carcinoma (LSY19H030002)
  • 🏅 Research Grant – Treating hyperuricemia-related NAFLD with Resveratrol (2014ZA090)
  • 🏅 Research Grant – Clinical value of CHI3L1 in chronic hepatitis B (2019KY532)

Publication Top Notes:

  • “An Integration of RNA Sequencing and Network Pharmacology Approaches Predicts the Molecular Mechanisms of the Huo-Xue-Shen Formula in the Treatment of Liver Fibrosis”  – 🧬📊
  • “Exosomes in Skin Flap Survival: Unlocking Their Role in Angiogenesis and Tissue Regeneration”  – 🧫🩺
  • “Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease” – 🧬❤️
  • “Exploring Tumor Heterogeneity in Colorectal Liver Metastases by Imaging: Unsupervised Machine Learning of Preoperative CT Radiomics Features for Prognostic Stratification”  – 🧠🤖
  • “Elevated Extracellular Matrix Protein 1 in Circulating Extracellular Vesicles Supports Breast Cancer Progression Under Obesity Conditions” – 🧬⚖️
  • “Untimely Surgery for Stent-Fracture-Related Death After Transjugular Intrahepatic Portosystemic Shunt: A Case Report” – 🩺📄
  • “Brevilin A is a Potent Anti-Metastatic CRC Agent That Targets the VEGF-IL6-STAT3 Axis in the HSCs-CRC Interplay”  – 🧬🛡️